Biologics, Bulls, and Billion‑Dollar Plus Bets: AbbVie’s Immunology $10.9B ‘Durability’ Shopping Spree Explained -( $ABBV $APGE $EPRX $REGN $SNY ) by John F. Heerdink, Jr. 2 days ago Read more Biologics, Blister Bulls, EOE and Yearly Shots: Why Sanofi and Eupraxia Belong on Every Immunology Watchlist -( $EPRX $REGN $SNY ) by John F. Heerdink, Jr. June 19, 2026 Read more When AI Meets Human Behaviour: How Butterfly, Midjourney, And Amwell Turn Radiologist Quirks Into Investor Optionality -( $AMWL $BFLY ) by John F. Heerdink, Jr. June 19, 2026 Read more Biotech Dealmaking & IPO Boom: What 2026’s $100 Billion Wave Means For Investors -( $AKTS $EIKN $IBB $MANE $SPTS $XBI ) by John F. Heerdink, Jr. June 18, 2026 Read more Simplify, Stick, Deliver: How Modular Medical’s Pivot Patch Pump Targets Millions Of “Almost-Pumpers” -( $MODD ) by John F. Heerdink, Jr. June 15, 2026 Read more Pods, Patches and Patient Psychology: How Diabetes Tech Is Turning Complexity into Cash Flow -( $MODD $PODD ) by John F. Heerdink, Jr. June 5, 2026 Read more Pivoting on Insulin: How Paul DiPerna’s New Insulin Pump Aims to Move Patients’ Blood Sugar — and Possibly Investors’ Portfolios -( $MODD $TNDM ) by John F. Heerdink, Jr. June 4, 2026 Read more Lilly’s Ascidian Bet and NewLimit’s ‘Anti-Aging’ $3B Valuation Show Biotech’s Newest Obsession: Rewriting Biology Itself -( $COIN $LLY $XBI ) by John F. Heerdink, Jr. June 3, 2026 Read more From EoE to CAR‑T: The Overachiever’s Guide to Eupraxia and Legend Biotech in 2026 -( $EPRX $JNJ $LEGN ) by John F. Heerdink, Jr. June 2, 2026 Read more Autodesk’s $3.6 Billion Wrench Turn: Why Wall Street Suddenly Loves Maintenance -( $ADSK $AMWL $FMC ) by John F. Heerdink, Jr. May 29, 2026 Read more Read more
